Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 10/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TK1 | P04183 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078295 | 1.00 | TK2 (0.51) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL14292729 | 1.00 | TK2 (0.51) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL13141383 | 0.93 | TK2 (0.43) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL14293138 | 0.92 | TK2 (0.61) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL3082518 | 0.86 | TK1 (0.48) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL13141385 | 0.85 | TK2 (0.52) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL17146890 | 0.84 | TK1 (0.60) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL3078268 | 0.84 | TK1 (0.46) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL11202018 | 0.83 | TK2 (0.59) | TK2CYP1A2CYP3A4TSHRTK1 | |
| SCHEMBL3082760 | 0.82 | TK2 (0.64) | TK2CYP1A2CYP3A4TSHRTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492537-B2 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy | RESPROTECT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | TK2 34/4885CYP1A2 2851/4885CYP3A4 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.